A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 14.3B | 14.3B | 14.2B | 13.1B | 12.2B | 16.1B |
| Net Income | 4.5B | 4.5B | 4.4B | 4.0B | 4.3B | 8.1B |
| EPS | $41.48 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Free Cash Flow | 4.1B | 4.1B | 3.7B | 3.9B | 4.4B | 6.5B |
| ROIC | 10.1% | 13.0% | 18.6% | 22.3% | 25.8% | 58.1% |
| Gross Margin | 88.6% | 88.6% | 88.8% | 88.5% | 89.1% | 87.0% |
| Debt/Equity | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.14 |
| Dividends/Share | $3.41 | $3.41 | $0.00 | $0.00 | - | - |
| Operating Income | 3.6B | 3.6B | 4.0B | 4.0B | 4.7B | 8.9B |
| Operating Margin | 24.9% | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% |
| ROE | 14.4% | 14.9% | 16.0% | 16.3% | 20.9% | 54.2% |
| Shares Outstanding | 109M | 109M | 115M | 114M | 114M | 112M |
REGENERON PHARMACEUTICALS, INC. passes 7 of 9 quality checks, indicating strong fundamentals.
REGENERON PHARMACEUTICALS, INC. trades at 18.0x trailing earnings, compared to its 15-year median P/E of 18.7x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 0.3x vs a median of 22.5x. The company's 5-year average ROIC is 27.6% with a gross margin of 88.4%. Total shareholder yield (dividends + buybacks) is 4.7%. At current prices, the estimated annualized return to fair value is +147.7%.
REGENERON PHARMACEUTICALS, INC. (REGN) has a current P/E ratio of 18.0, compared to its historical median P/E of 18.7. The stock is currently considered Fair based on its historical valuation range.
REGENERON PHARMACEUTICALS, INC. (REGN) has a 5-year average return on invested capital (ROIC) of 27.6%. This indicates strong capital allocation and a potential competitive advantage.
REGENERON PHARMACEUTICALS, INC. (REGN) has a market capitalization of $81.1B. It is classified as a large-cap stock.
Yes, REGENERON PHARMACEUTICALS, INC. (REGN) pays a dividend with a trailing twelve-month yield of 0.46%. The company also returns capital through share buybacks, with a buyback yield of 4.24%.
Based on historical P/E analysis, REGENERON PHARMACEUTICALS, INC. (REGN) appears fair. The current P/E of 18.0 is 4% below its historical median of 18.7. The estimated fair value CAGR (P/E method) is 11.6%.
REGENERON PHARMACEUTICALS, INC. (REGN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
REGENERON PHARMACEUTICALS, INC. (REGN) reported annual revenue of $14.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
REGENERON PHARMACEUTICALS, INC. (REGN) has a net profit margin of 31.4%. This is a strong margin indicating high profitability.
REGENERON PHARMACEUTICALS, INC. (REGN) generated $4.1 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
REGENERON PHARMACEUTICALS, INC. (REGN) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
REGENERON PHARMACEUTICALS, INC. (REGN) reported earnings per share (EPS) of $41.48 in its most recent fiscal year.
REGENERON PHARMACEUTICALS, INC. (REGN) has a return on equity (ROE) of 14.9%. This indicates moderate shareholder returns.
REGENERON PHARMACEUTICALS, INC. (REGN) has a 5-year average gross margin of 88.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 18 years of financial data for REGENERON PHARMACEUTICALS, INC. (REGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
REGENERON PHARMACEUTICALS, INC. (REGN) has a book value per share of $287.81, based on its most recent annual SEC filing.